Cargando…

Lomeguatrib Increases the Radiosensitivity of MGMT Unmethylated Human Glioblastoma Multiforme Cell Lines

Background: Treatment resistance of glioblastoma multiforme to chemo- and radiotherapy remains a challenge yet to overcome. In particular, the O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter unmethylated patients have only little benefit from chemotherapy treatment using temozolomide since...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kirstein, Anna, Schilling, Daniela, Combs, Stephanie E., Schmid, Thomas E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268804/ https://www.ncbi.nlm.nih.gov/pubmed/34202589 http://dx.doi.org/10.3390/ijms22136781

Ejemplares similares

The Role of miRNA for the Treatment of MGMT Unmethylated Glioblastoma Multiforme
por: Kirstein, Anna, et al.
Publicado: (2020)

Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma
por: Jue, Toni Rose, et al.
Publicado: (2017)

Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival
por: Rahman, Mohummad Aminur, et al.
Publicado: (2019)

A case study of a long-term glioblastoma survivor with unmethylated MGMT and hypermutated genotype
por: Jue, Toni Rose, et al.
Publicado: (2019)

A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study
por: Sim, Hao-Wen, et al.
Publicado: (2021)

Homogeneous MGMT Immunoreactivity Correlates with an Unmethylated MGMT Promoter Status in Brain Metastases of Various Solid Tumors
por: Ingold, Barbara, et al.
Publicado: (2009)

Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis
por: Alnahhas, Iyad, et al.
Publicado: (2020)

A Novel DNA Methylation-Based Signature Can Predict the Responses of MGMT Promoter Unmethylated Glioblastomas to Temozolomide
por: Chai, Rui-Chao, et al.
Publicado: (2019)

Phase II trial of concurrent sunitinib, temozolomide, and radiotherapy with adjuvant temozolomide for newly diagnosed MGMT unmethylated glioblastoma
por: Faye, Mame Daro, et al.
Publicado: (2023)

Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial
por: Omuro, Antonio, et al.
Publicado: (2022)

Immune-Related lncRNA Risk Signatures Predict Survival of IDH Wild-Type and MGMT Promoter Unmethylated Glioblastoma
por: Li, Xiaozhi, et al.
Publicado: (2020)

Erratum to: Characterizing Benefit from Temozolomide in MGMT Promoter Unmethylated and Methylated Glioblastoma: A Systematic Review and Meta-analysis
por: Alnahhas, Iyad, et al.
Publicado: (2021)

Dodecafluoropentane Emulsion as a Radiosensitizer in Glioblastoma Multiforme
por: Lickliter, Jason D., et al.
Publicado: (2023)

Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours
por: Tawbi, H A, et al.
Publicado: (2011)

Modification of radiosensitivity by Curcumin in human pancreatic cancer cell lines
por: Schwarz, Katharina, et al.
Publicado: (2020)

IM-2 Possibility of immunotherapy for the glioblastoma patients with O6-methyl-guanine DNA methyltransferase (MGMT) expression or promoter unmethylated
por: Kushihara, Yoshihiro, et al.
Publicado: (2021)

Treatment of unmethylated MGMT-promoter recurrent glioblastoma with cancer stem cell assay-guided chemotherapy and the impact on patients’ healthcare costs
por: Ranjan, Tulika, et al.
Publicado: (2023)

MGMT and Whole-Genome DNA Methylation Impacts on Diagnosis, Prognosis and Therapy of Glioblastoma Multiforme
por: Della Monica, Rosa, et al.
Publicado: (2022)

In Vitro Radiosensitizing Effects of Temozolomide on U87MG Cell Lines of Human Glioblastoma Multiforme
por: Borhani, Samira, et al.
Publicado: (2017)

SYST-11 PHASE 2 STUDY OF VAL-083 AND RADIOTHERAPY IN NEWLY DIAGNOSED MGMT-UNMETHYLATED GBM
por: Chen, Zhongping, et al.
Publicado: (2022)

Combined Therapy Sensitivity Index Based on a 13-Gene Signature Predicts Prognosis for IDH Wild-type and MGMT Promoter Unmethylated Glioblastoma Patients
por: Ye, Ningrong, et al.
Publicado: (2019)

Epigenetic modulation of the drug resistance genes MGMT, ABCB1 and ABCG2 in glioblastoma multiforme
por: Oberstadt, Moritz C, et al.
Publicado: (2013)

Radiosensitizing high-Z metal nanoparticles for enhanced radiotherapy of glioblastoma multiforme
por: Choi, Jinyeong, et al.
Publicado: (2020)

The use of radiosensitizing agents in the therapy of glioblastoma multiforme—a comprehensive review
por: Pepper, Niklas Benedikt, et al.
Publicado: (2022)

A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer
por: Khan, O A, et al.
Publicado: (2008)

A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer
por: Khan, O A, et al.
Publicado: (2009)

Treatment of MGMT promoter unmethylated glioblastoma with PD-1 inhibitor combined with anti-angiogenesis and epidermal growth factor receptor tyrosine kinase inhibitor: a case report
por: Wang, Zheng, et al.
Publicado: (2021)

A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma
por: Kefford, R F, et al.
Publicado: (2009)

Radiosensitization by Kinase Inhibition Revealed by Phosphoproteomic Analysis of Pancreatic Cancer Cells
por: Wiechmann, Svenja, et al.
Publicado: (2020)

Impact of delays in initiating postoperative chemoradiation while determining the MGMT promoter-methylation statuses of patients with primary glioblastoma
por: Adeberg, Sebastian, et al.
Publicado: (2015)

Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?
por: Combs, Stephanie E, et al.
Publicado: (2011)

Up-regulation of miR-370-3p restores glioblastoma multiforme sensitivity to temozolomide by influencing MGMT expression
por: Gao, Yong-tao, et al.
Publicado: (2016)

Maintaining the unmethylated state
por: Smith, Steven S
Publicado: (2013)

Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT) – phase I/II trial: study protocol
por: Combs, Stephanie E, et al.
Publicado: (2006)

Association between MGMT Enhancer Methylation and MGMT Promoter Methylation, MGMT Protein Expression, and Overall Survival in Glioblastoma
por: Zappe, Katja, et al.
Publicado: (2023)

Long-Term Cultured Human Glioblastoma Multiforme Cells Demonstrate Increased Radiosensitivity and Senescence-Associated Secretory Phenotype in Response to Irradiation
por: Alhaddad, Lina, et al.
Publicado: (2023)

Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
por: Van Gool, Stefaan W., et al.
Publicado: (2022)

Glioblastoma Multiforme
por: Sheehan, Jonas M., et al.
Publicado: (2012)

Prospective study evaluating the radiosensitizing effect of reduced doses of temozolomide in the treatment of Egyptian patients with glioblastoma multiforme
por: Gaber, May, et al.
Publicado: (2013)

Cellular and Molecular Comparison of Glioblastoma Multiform Cell Lines
por: Demircan, Turan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dba5vucnupfor8uhe0leoug66b